Strategic Partnerships Gensaic already collaborates with Novo Nordisk and has active pharma engagement, signaling strong buyer interest in tissue targeted delivery. Target other large pharma and biotech firms for co development licensing of FORGE based tissue selective ligands and RNA payload delivery, with flexible collaboration structures.

AI Powered Differentiator FORGE merges phage display with generative AI to deliver unbiased directed evolution and enhanced tissue selectivity. Position as a discovery service or platform for customers seeking rapid, validated protein engineering results; offer pilot engagements or white label options.

RNA Delivery Focus Initial emphasis on siRNA payloads aligns with demand for tissue targeted RNA therapies. Sales angle pursue RNA therapeutics developers, gene therapy companies, and CROs with end to end discovery and optimization for tissue specific delivery.

Market Validation Recent high profile collaborations and partnerships demonstrate real market interest and potential scale. Use these as proof points in outreach; propose milestone based or risk sharing deals and early access pilots.

Ecosystem and Scale Based in Cambridge with MIT roots and a cloud first tech stack, Gensaic has access to top academic talent and scalable AI enabled discovery. Leverage this ecosystem to pursue sponsored research, co development ventures, and enterprise grade collaboration with data driven pipelines.